Physician profile
Daren Primack
NPI 1215905260
$234,321.74
in general payments reported to CMS, 2019-2025
39 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $27K · 2021: $29K · 2022: $37K · 2023: $49K · 2024: $5,827 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $3,300 · Travel and Lodging: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,359.00 |
| Food and Beverage | $3,300.42 |
| Travel and Lodging | $1,126.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154,193.59 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61,004.32 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $13,365.32 | 2019-2023 | Jardiance |
| Medtronic Vascular, INC. | $1,300.78 | 2019 | |
| Abiomed | $705.77 | 2019-2024 | Impella |
| Abbott Laboratories | $453.68 | 2019-2024 | Gallant, Mitraclip |
| Novartis Pharmaceuticals Corporation | $370.80 | 2019-2025 | |
| Johnson & Johnson Health Care Systems INC. | $261.92 | 2019-2025 | Stelara, Tremfya, Rybrevant |
| Boston Scientific Corporation | $252.66 | 2019-2024 | Watchman Flx, Ranger, Latitude Communicator Power Supply |
| Astrazeneca Pharmaceuticals LP | $229.68 | 2019-2025 | Farxiga |
| Impulse Dynamics (USA) INC. | $224.93 | 2023-2024 | Optimizer, Optimizer |
| Medtronic, INC. | $218.08 | 2021-2025 | Venaseal, Reveal Linq, Linq II |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Amgen INC. | $193.89 | 2019-2023 | Repatha |
| Avinger INC. | $171.13 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $167.42 | 2023-2025 | (5044) Mcot, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Merck Sharp & Dohme LLC | $152.01 | 2022-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.29 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $88.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.10 | 2021-2025 | |
| Cagent Vascular INC | $57.82 | 2023 | Serrantor |
| Pfizer INC. | $44.83 | 2019 | |
| Tactile Systems Technology INC | $43.62 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Lexicon Pharmaceuticals, INC. | $40.23 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $39.54 | 2020-2021 | |
| Astellas Pharma US INC | $36.56 | 2019-2020 | |
| Biotronik INC. | $35.48 | 2019 | |
| Novo Nordisk INC | $33.41 | 2021-2023 | Rybelsus, Ozempic |
| Bardy Diagnostics, INC. | $32.08 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $29.78 | 2019 | |
| Osprey Medical INC | $27.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $26.35 | 2025 | Opsumit |
| Resmed Corp | $25.34 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $23.55 | 2021 | |
| Angiodynamics, INC. | $22.37 | 2023 | Auryon Laser System 100-120 Vac |
| Shockwave Medical, INC | $20.62 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.22 | 2023 | Eliquis |
| Baxter Healthcare | $13.04 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daren Primack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.